NASDAQ$INKT

Mink Therapeutics Inc · Q4 2021 earnings

Q4 2021 earnings · · Investor relations

Headline financials

Total Revenue

$222M

No prior period
EPS (adj)

-$0.18

Previous: -$0.05-233.0%
Capital Expenditures

-$277.00

No prior period
Free Cash Flow

-$1.7M

No prior period
Net Income

-$5.76M

Previous: -$1.54M-275.5%
Operating Income

-$6.36M

Previous: -$1.52M-317.3%
Cash & Equivalents

$38.9M

No prior period
Total Assets

$40.2M

No prior period
Stock-Based Comp

$667K

No prior period

Revenue & EPS history

Mink Therapeutics · Revenue · Quarterly

$222M

Q4 2021

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q4 2021

Historical avgQ4 2021

-3.6%

Avg return

Earnings day

-4.9%

Avg return

5 days after

-1.7%

Avg return

30 days after

42%

8 / 19 earnings

Positive

+14.6%

Q3 2022

Best reaction

-42.0%

Q2 2021

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026+3.9%+2.2%+13.3%
Q3 2025-1.9%-16.6%-6.1%
Q2 2025-13.6%-16.0%-17.7%
Q1 2025-3.3%-3.8%-3.3%
Q4 2024-3.3%+6.8%-14.9%
Q3 2024-5.0%-13.5%-22.4%
Q2 2024+0.6%-3.0%-8.5%
Q1 2024+6.1%+3.1%-1.4%
Q4 2023-2.9%+4.7%-2.2%
Q3 2023-11.8%-20.2%-14.3%
Q2 2023+1.7%-5.0%-26.1%
Q1 2023+13.9%+11.3%+44.4%
Q4 2022+0.5%-3.4%-3.4%
Q3 2022+14.6%+17.8%+18.3%
Q2 2022+13.2%+25.7%+114.7%
Q1 2022-26.7%-26.7%-13.1%
Q4 2021-6.1%-4.2%-5.5%
Q3 2021-6.1%-4.2%-5.5%
Q2 2021-42.0%-47.6%-78.6%
Q1 2021
Q4 2020
Q3 2020
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro